Sirtuin 6 Regulates the Activation of the ATP/Purinergic Axis in Endothelial Cells

Int J Mol Sci. 2023 Apr 4;24(7):6759. doi: 10.3390/ijms24076759.

Abstract

Sirtuin 6 (SIRT6) is a member of the mammalian NAD+-dependent deac(et)ylase sirtuin family. SIRT6's anti-inflammatory roles are emerging increasingly often in different diseases and cell types, including endothelial cells. In this study, the role of SIRT6 in pro-inflammatory conditions was investigated by engineering human umbilical vein endothelial cells to overexpress SIRT6 (SIRT6+ HUVECs). Our results showed that SIRT6 overexpression affected the levels of adhesion molecules and sustained megakaryocyte proliferation and proplatelet formation. Interestingly, the pro-inflammatory activation of the ATP/purinergic axis was reduced in SIRT6+ HUVECs. Specifically, the TNFα-induced release of ATP in the extracellular space and the increase in pannexin-1 hemichannel expression, which mediates ATP efflux, were hampered in SIRT6+ cells. Instead, NAD+ release and Connexin43 expression were not modified by SIRT6 levels. Moreover, the Ca2+ influx in response to ATP and the expression of the purinergic receptor P2X7 were decreased in SIRT6+ HUVECs. Contrary to extracellular ATP, extracellular NAD+ did not evoke pro-inflammatory responses in HUVECs. Instead, NAD+ administration reduced endothelial cell proliferation and motility and counteracted the TNFα-induced angiogenesis. Altogether, our data reinforce the view of SIRT6 activation as an anti-inflammatory approach in vascular endothelium.

Keywords: ATP; NAD+; SIRT6; endothelium; inflammation; purinergic receptors.

MeSH terms

  • Adenosine Triphosphate
  • Human Umbilical Vein Endothelial Cells* / metabolism
  • Humans
  • NAD
  • Sirtuins* / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Adenosine Triphosphate
  • NAD
  • SIRT6 protein, human
  • Sirtuins
  • Tumor Necrosis Factor-alpha